Cited by 3,066Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 65 of the 68 references it cites were found in a registry or an index.

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

Open access

Inzucchi, Silvio E., Bergenstal, Richard M., Buse, John B., Diamant, Michaela, Ferrannini, Ele, Nauck, Michael, Peters, Anne L., Tsapas, Apostolos, Wender, Richard, Matthews, David R.·2015·Diabetes Care

DOI 10.2337/dc14-2441

Open this paper in CoChat — free account

Abstract

In 2012, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a position statement on the management of hyperglycemia in patients with type 2 diabetes (1,2). This was needed because of an increasing array of antihyperglycemic drugs and growing uncertainty regarding their proper selection and sequence. Because of a paucity of comparative effectiveness research on long-term treatment outcomes with many of these medications, the 2012 publication was less prescriptive than prior consensus reports. We previously described the need to individualize both treatment targets and treatment strategies, with an emphasis on patient-centered care and shared decision making, and this continues to be our position, although there are now more head-to-head trials that show slight variance between agents with regard to glucose-lowering effects. Nevertheless, these differences are often small and would be unlikely to reflect any definite differential effect in an individual patient. The ADA and EASD have requested an update to the position statement incorporating new data from recent clinical trials. Between June and September of 2014, the Writing Group reconvened, including one face-to-face meeting, to discuss the changes. An entirely new statement was felt to be unnecessary. Instead, the group focused on those areas where revisions were suggested by a changing evidence base. This briefer article should therefore be read as an addendum to the previous full account (1,2). Glucose control remains a major focus in the management of patients with type 2 diabetes. However, this should always be in the context of a comprehensive cardiovascular risk factor reduction program, to include smoking cessation and the adoption of other healthy lifestyle habits, blood pressure control, lipid management with priority to statin medications, and, in some circumstances, antiplatelet therapy. Studies have conclusively determined that reducing hyperglycemia decreases the onset and progression of …

Integrity signals

Registry

Crossref · 10.2337/dc14-2441

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citation
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citation
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Self-citation
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Self-citation

Flagged first, then by citations

Show all 68 references

3 of the 68 references couldn’t be matched to a known paper.

Sorted by citations

Items 801–900 of 1,014

Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus
Garnock-Jones, K. P. (2017) · Drugs · doi:10.1007/s40265-017-0697-1 · Cited by 33
LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice
Powell, D. R., Smith, M. G., Doree, D. D., Harris, A. L., Greer, J., DaCosta, C. M., Thompson, A. Y., Jeter-Jones, S. L., Xiong, W., Carson, K. G., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.240820 · Cited by 33
The Economic Burden of Insulin-Related Hypoglycemia in Spain
Parekh, W., Hoskins, N., Baker‐Knight, J., de Arellano, A. R., & Raya, P. M. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0285-0 · Cited by 33
When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy
Avogaro, A., Delgado, E., & Lingvay, I. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2981 · Cited by 34
A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products
Nuffer, W. A., Guesnier, A., & Trujillo, J. M. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018817752315 · Cited by 33
Should metformin remain first-line medical therapy for patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease? An alternative approach
Harrington, J. L., de Albuquerque Rocha, N., Patel, K. V., Verma, S., & McGuire, D. K. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1035-z · Cited by 32
The Impact of a Nutritional Intervention on Glycemic Control and Cardiovascular Risk Markers in Type 2 Diabetes
Minari, T. P., Manzano, C. F., Tácito, L. H. B., Yugar, L. B. T., Sedenho‐Prado, L. G., Rubio, T. D. A., Pires, A. C., Vilela-Martin, J. F., Cosenso‐Martin, L. N., Moreno, H., et al. (2024) · Nutrients · doi:10.3390/nu16091378 · Cited by 32
Endocrine and Metabolic Mechanisms Linking Obesity to Type 2 Diabetes: Implications for Targeted Therapy
Allocca, S., Monda, A., Messina, A., Casillo, M., Sapuppo, W., Monda, V., Polito, R., Maio, G. D., Monda, M., & Marra, M. L. (2025) · Healthcare · doi:10.3390/healthcare13121437 · Cited by 32
Comparative cardiovascular safety of glucagon‐like peptide‐1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study
Patorno, E., Everett, B. M., Goldfine, A. B., Glynn, R. J., Liu, J., Gopalakrishnan, C., & Kim, S. C. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12665 · Cited by 32
Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes
Tan, X., & Hu, J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1183645 · Cited by 32
Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What’s the Fuss?
Bakris, G. L., & Molitch, M. E. (2016) · Diabetes Care · doi:10.2337/dc15-2534 · Cited by 32
Metformin
Tan, M. H., Alquraini, H., Mizokami‐Stout, K., & MacEachern, M. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.008 · Cited by 33
National Clinical Guidelines
(2017) · The American Pharmacists Association eBooks · doi:10.21019/9781582122885.nationalclinicalguidelines · Cited by 32
Experience of Home Telehealth Technology in Older Patients With Diabetes
Chang, C.-P., Lee, T., & Mills, M. E. (2017) · CIN Computers Informatics Nursing · doi:10.1097/cin.0000000000000341 · Cited by 32
Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus
Fujieda, H., Kogami, M., Sakairi, M., Kato, N., Makino, M., Takahashi, N., Miyazawa, T., Harada, S., & Yamashita, T. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.06.060 · Cited by 32
Metformin Promotes Beclin1-Dependent Autophagy to Inhibit the Progression of Gastric Cancer
Liu, S., Yue, C., Chen, H., Chen, Y., & Li, G. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s242298 · Cited by 32
Antimicrobial Susceptibility Testing and Phenotypic Detection of MRSA Isolated from Diabetic Foot Infection
Anwar, K. A., Hussein, D. M., & Salih, J. M. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s278574 · Cited by 32
Patient Work and Treatment Burden in Type 2 Diabetes: A Mixed-Methods Study
Spencer‐Bonilla, G., Serrano, V., Gao, C. C., Sanchez, M., Carroll, K., Gionfriddo, M. R., Behnken, E., Hargraves, I. G., Boehmer, K. R., May, C. R., et al. (2021) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2021.01.006 · Cited by 32
Effects of diet and antihyperglycemic drugs on erectile dysfunction: A systematic review
Defeudis, G., Mazzilli, R., Tommaso, A. M. D., Zamponi, V., Carlomagno, F., Tuccinardi, D., Watanabe, M., Faggiano, A., & Gianfrilli, D. (2022) · Andrology · doi:10.1111/andr.13192 · Cited by 32
Examining factors associated with excess mortality in older people (age ≥ 70 years) with diabetes – a 10‐year cohort study of older people with and without diabetes
Forbes, A., Murrells, T., & Sinclair, A. J. (2016) · Diabetic Medicine · doi:10.1111/dme.13132 · Cited by 32
Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma
Hamieh, L., McKay, R. R., Lin, X., Moreira, R. B., Simantov, R., & Choueiri, T. K. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.06.017 · Cited by 32
Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study
Roussel, R., Charbonnel, B. H., Behar, M., Gourmelen, J., Emery, C., & Detournay, B. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0185-8 · Cited by 32
Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview
Davidson, J. A., & Sloan, L. A. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0434-2 · Cited by 32
Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom
Qin, L., Chen, S., Flood, E. M., Shaunik, A., Romero, B., de la Cruz, M., Alvarez, C., & Grandy, S. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0237-8 · Cited by 32
Response to Comments on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140–149
Inzucchi, S. E., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc15-0812 · Cited by 32
Self-citation
Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study
Ueda, P., Wintzell, V., Melbye, M., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., Svanström, H., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05508-1 · Cited by 31
Socio-demographic, behavioural and clinical factors influencing control of diabetes and hypertension in urban Mysore, South India: a mixed-method study conducted in 2018
Dey, S., Mukherjee, A., Pati, M. K., Kar, A., Ramanaik, S., Pujar, A., Malve, V., Mohan, H. L., Jayanna, K., & Swaroop, N. (2022) · Archives of Public Health · doi:10.1186/s13690-022-00996-y · Cited by 31
Adverse effects of incretin‐based therapies on major cardiovascular and arrhythmia events: meta‐analysis of randomized trials
Wang, T., Wang, F., Zhou, J., Tang, H., & Giovenale, S. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2804 · Cited by 31
New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?
Standl, E., & Owen, D. R. (2016) · Diabetes Care · doi:10.2337/dcs15-3011 · Cited by 31
Center-based patient care enhances survival of elderly patients suffering from peripheral arterial disease
Höbaus, C., Herz, C. T., Obendorf, F., Howanietz, M.-T., Wrba, T., Koppensteiner, R., & Schernthaner, G.-H. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1241428 · Cited by 31
Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US
Lin, J., Lingohr-Smith, M., & Fan, T. (2016) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s117200 · Cited by 31
Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide
Brønden, A., Knop, F. K., & Christensen, M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0499-8 · Cited by 31
Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden
Ericsson, Å., & Lundqvist, A. (2017) · Applied Health Economics and Health Policy · doi:10.1007/s40258-016-0301-y · Cited by 31
Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
Lau, I. T., Lee, K. F., So, W. Y., Tan, K. C. B., & Yeung, M. W. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s131358 · Cited by 31
Diabetic Kidney Disease
Tong, L., & Adler, S. G. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04650417 · Cited by 31
Low 1,5-anhydroglucitol levels are associated with long-term cardiac mortality in acute coronary syndrome patients with hemoglobin A1c levels less than 7.0%
Ouchi, S., Shimada, K., Miyazaki, T., Takahashi, S., Sugita, Y., Shimizu, M., Murata, A., Kadoguchi, T., Kato, T., Aikawa, T., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0636-1 · Cited by 31
Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study
Blevins, T., Barve, A. J., Sun, B., Raiter, Y., Aubonnet, P., Muniz, R., Athalye, S. N., & Ankersen, M. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13495 · Cited by 31
Informed shared decision-making programme for patients with type 2 diabetes in primary care: cluster randomised controlled trial
Buhse, S., Kuniß, N., Liethmann, K., Müller, U., Lehmann, T., & Mühlhauser, I. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-024004 · Cited by 31
Impacts of nurse-led clinic and nurse-led prescription on hemoglobin A1c control in type 2 diabetes
Wang, Q., Shen, Y., Chen, Y., & Li, X. (2019) · Medicine · doi:10.1097/md.0000000000015971 · Cited by 31
Total Synthesis of Semaglutide Based on a Soluble Hydrophobic-Support-Assisted Liquid-Phase Synthetic Method
Liu, X., Zhang, N., Gu, X., Qin, Y., Song, D., Zhang, L., & Ma, S. (2020) · ACS Combinatorial Science · doi:10.1021/acscombsci.0c00134 · Cited by 31
“When nothing happens, nobody is afraid!” beliefs and perceptions around self‐care and health‐seeking behaviours: Voices of patients living with diabetic lower extremity amputation in primary care
Zhu, X., Lee, M., Chew, E. A., Goh, L. J., Dong, L., & Bartlam, B. (2021) · International Wound Journal · doi:10.1111/iwj.13587 · Cited by 31
Impact of non-antibiotic drugs on the human intestinal microbiome
Bastard, Q. L., Berthelot, L., Soulillou, J., & Montassier, E. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1952075 · Cited by 31
Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations
Ceriello, A., & Inagaki, N. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12528 · Cited by 31
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION ‐8 randomized controlled trial
Frías, J. P., Hardy, E., Ahmed, A., Öhman, P., Jabbour, S. A., Wang, H., & Guja, C. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13296 · Cited by 31
Development of an Injectable Slow-Release Metformin Formulation and Evaluation of Its Potential Antitumor Effects
Baldassari, S., Solari, A., Zuccari, G., Drava, G., Pastorino, S., Fucile, C., Marini, V., Daga, A., Pattarozzi, A., Ratto, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22054-w · Cited by 31
Effect of a mindfulness programme for long-term care residents with type 2 diabetes: a cluster randomised controlled trial measuring outcomes of glycaemic control, relocation stress and depression
Chen, S., Lin, H., Atherton, J. J., MacIsaac, R. J., & Wu, C. (. (2020) · International Journal of Older People Nursing · doi:10.1111/opn.12312 · Cited by 30
Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting
Davies, M. J., Glah, D. R., Chubb, B., Konidaris, G., & McEwan, P. C. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0433-9 · Cited by 30
Risks of Metformin in Type 2 Diabetes and Chronic Kidney Disease: Lessons Learned from Taiwanese Data
Rhee, C. M., Kovesdy, C. P., & Kalantar‐Zadeh, K. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000450862 · Cited by 30
A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes
Genovese, S., Mannucci, E., & Ceriello, A. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0499-6 · Cited by 30
Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes)
Fadini, G. P., Zatti, G., Consoli, A., Bonora, E., Sesti, G., Avogaro, A., Consoli, A., Formoso, G., Antenucci, D., Grossi, G., et al. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.08.001 · Cited by 30
Individualized Glycemic Goals and an Expanded Classification of Severe Hypoglycemia in Diabetes
Cryer, P. E. (2017) · Diabetes Care · doi:10.2337/dc16-1741 · Cited by 30
Use of sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations
Deerochanawong, C., Chan, S. P., Matawaran, B. J., Sheu, W. H., Chan, J. C. N., Man, N. H., Suastika, K., Khoo, C. M., Yoon, K., Luk, A. O. Y., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13819 · Cited by 30
Effect of the FreeStyle Libre™ flash glucose monitoring system on glycemic control in individuals with type 2 diabetes treated with basal–bolus insulin therapy: An open label, prospective, multicenter trial in Japan
Ogawa, W., Hirota, Y., Osonoi, T., Tosaki, T., Kato, Y., Utsunomiya, K., Nishimura, R., & Nakamura, J. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13327 · Cited by 30
The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome
Sultana, R., Sissoho, F., Kaushik, V. P., & Raji, M. A. (2022) · Life · doi:10.3390/life12081222 · Cited by 30
Hypoglycemia and Comorbidities in Type 2 Diabetes
Kong, A. P. S., & Chan, J. C. N. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0646-x · Cited by 30
Combination therapy for type 2 diabetes: dapagliflozin plus metformin
Tan, X., & Hu, J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1121235 · Cited by 30
Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation
Loganadan, N. K., Huri, H. Z., Vethakkan, S. R., & Hussein, Z. B. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2015.95 · Cited by 30
Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data
Davies, M. J., Merton, K., Vijapurkar, U., Yee, J., & Qiu, R. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0517-7 · Cited by 30
Impact on Diabetes Self-Management and Glycemic Control of a New Color-Based SMBG Meter
Schnell, O., Klausmann, G., Gutschek, B., García-Verdugo, R., & Hummel, M. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817706376 · Cited by 30
Why prescribe exercise as therapy in type 2 diabetes? We have a pill for that!
Ried‐Larsen, M., MacDonald, C. S., Johansen, M. Y., Hansen, K. B., Christensen, R., Almdal, T. P., Pedersen, B. K., & Karstoft, K. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2999 · Cited by 29
Effect of Total Daily Dose on Efficacy, Dosing, and Safety of 2 Dose Titration Regimens of Human Regular U-500 Insulin in Severely Insulin-Resistant Patients with Type 2 Diabetes
Wysham, C., Hood, R. C., Warren, M. L., Wang, T., Morwick, T. M., & Jackson, J. A. (2016) · Endocrine Practice · doi:10.4158/ep15959.or · Cited by 29
IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy
Freemantle, N., Mamdani, M., Vilsbøll, T., Kongsø, J. H., Kvist, K., & Bain, S. C. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0142-y · Cited by 29
Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy
Monnier, L., Colette, C., Dejager, S., & Owens, D. R. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9325-8 · Cited by 29
A review of glucagon‐like peptide‐1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus
Owens, D. R., Monnier, L., & Hanefeld, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12998 · Cited by 29
Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis
Yoon, J., Min, S. H., Ahn, C. H., Cho, Y. M., & Hahn, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-22443-1 · Cited by 29
Changing the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited
Saisho, Y. (2018) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530318666180821161825 · Cited by 29
Glucocentric risk factors for macrovascular complications in diabetes: Glucose ‘legacy’ and ‘variability’-what we see, know and try to comprehend
Monnier, L., Colette, C., Schlienger, J.-L., Bauduceau, B., & Owens, D. R. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.007 · Cited by 29
Prognostic impact of visit-to-visit glycemic variability on the risks of major adverse cardiovascular outcomes and hypoglycemia in patients with different glycemic control and type 2 diabetes
Sun, B., He, F., Gao, Y., Zhou, J., Sun, L., Liu, R., Xu, H. Y., Chen, X., Zhou, H., Liu, Z., et al. (2019) · Endocrine · doi:10.1007/s12020-019-01893-1 · Cited by 29
Feasibility Studies on Nafion Membrane Actuated Micropump Integrated With Hollow Microneedles for Insulin Delivery Device
Mishra, R., Maiti, T. K., & Bhattacharyya, T. K. (2019) · Journal of Microelectromechanical Systems · doi:10.1109/jmems.2019.2939189 · Cited by 29
Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care
Jacob, S., Krentz, A. J., Deanfield, J. E., & Rydén, L. (2021) · Drugs · doi:10.1007/s40265-021-01554-6 · Cited by 29
Metformin reverses tamoxifen resistance through the lncRNA GAS5-medicated mTOR pathway in breast cancer
Jiang, Y., Qian, T., Li, S., Xie, Y., & Tao, M. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-795 · Cited by 29
Methicillin-Resistant Staphylococcus aureus in Diabetic Foot Infections: Protein Profiling, Virulence Determinants, and Antimicrobial Resistance
Abalkhail, A., & Elbehiry, A. (2022) · Applied Sciences · doi:10.3390/app122110803 · Cited by 29
Dulaglutide: A Review in Type 2 Diabetes
Burness, C. B., & Scott, L. J. (2015) · BioDrugs · doi:10.1007/s40259-015-0143-4 · Cited by 29
Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus
Mikhail, N. E. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1061501 · Cited by 29
Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus
Triplitt, C. L., Solis‐Herrera, C., Cersósimo, E., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1114098 · Cited by 29
Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis
Zhong, X., Lai, D., Ye, Y., Yang, X., Yu, B., & Huang, Y. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2010-8 · Cited by 29
Therapeutics for Equine Endocrine Disorders
Durham, A. E. (2017) · Veterinary Clinics of North America Equine Practice · doi:10.1016/j.cveq.2016.11.003 · Cited by 30
Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes
Quartuccio, M., Buta, B. J., & Kalyani, R. R. (2017) · Current Geriatrics Reports · doi:10.1007/s13670-017-0215-z · Cited by 29
Diabetes Mellitus Treatment
Khoo, C. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803678-5.00108-9 · Cited by 29
A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects
Ikushima, I., Jensen, L., Flint, A., Nishida, T., Zacho, J., & Irie, S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0677-1 · Cited by 28
Leukocyte telomere length correlates with glucose control in adults with recently diagnosed type 2 diabetes
Rosa, E. C. C. C., dos Santos, R. R. C., Fernandes, L. F. A., Neves, F. D. A. R., Coelho, M. S., & Amato, A. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.10.020 · Cited by 28
Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases
Li, Y., Li, L., & Hölscher, C. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0018 · Cited by 28
Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis
Wysham, C., Lin, J., & Kuritzky, L. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1297669 · Cited by 28
Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence
Carls, G. S., Tan, R., Zhu, J., Tuttle, E., Yee, J., Edelman, S. V., & Polonsky, W. H. (2017) · Obesity Science & Practice · doi:10.1002/osp4.116 · Cited by 28
An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin
Evans, M., Billings, L. K., Håkan‐Bloch, J., Slothuus, U., Abrahamsen, T. J., Andersen, A., & Jansen, J. P. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1409228 · Cited by 28
Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
Nishimura, R., Tanaka, Y., Koiwai, K., Ishida, K., Salsali, A., Kaspers, S., Köhler, S., & Lund, S. S. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01045-x · Cited by 28
User Centered Design to Improve Information Exchange in Diabetes Care Through eHealth
Fico, G., Martínez-Millana, A., Leuteritz, J., Fioravanti, A., Beltrán, M. E., Traver, V., & Arredondo, M. T. (2019) · Journal of Medical Systems · doi:10.1007/s10916-019-1472-5 · Cited by 28
A Practitioner’s Toolkit for Insulin Motivation in Adults with Type 1 and Type 2 Diabetes Mellitus: Evidence-Based Recommendations from an International Expert Panel
Kalra, S., Bajaj, S., Sharma, S. K., Priya, G., Baruah, M. P., Sanyal, D., Das, S., Chaudhury, T., Gangopadhyay, K. K., Das, A. K., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00764-7 · Cited by 28
Inhibition Mechanism of Components Isolated from Morus alba Branches on Diabetes and Diabetic Complications via Experimental and Molecular Docking Analyses
Kwon, R. H., Thaku, N., Timalsina, B., Park, S., Choi, J. S., & Jung, H. (2022) · Antioxidants · doi:10.3390/antiox11020383 · Cited by 28
Diabetology and oncology meet in a network model: union is strength
Gallo, M., Gentile, L., Arvat, E., Bertetto, O., & Clemente, G. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0839-z · Cited by 28
Bariatric Surgery in Obese Patients with Type 1 Diabetes: Effects on Weight Loss and Metabolic Control
Faucher, P., Poitou, C., Carette, C., du Montcel, S. T., Barsamian, C., Touati, E.-B., Bouillot, J., Torcivia, A., Czernichow, S., Oppert, J., et al. (2016) · Obesity Surgery · doi:10.1007/s11695-016-2106-3 · Cited by 28
Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial
Karagiannis, T., Liakos, A., Branda, M. E., Athanasiadou, E. A., Mainou, M., Boura, P., Goulis, D. G., LeBlanc, A., Montori, V. M., & Τσάπας, Α. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012185 · Cited by 28
Extending Metformin Use in Diabetic Kidney Disease: A Pharmacokinetic Study in Stage 4 Diabetic Nephropathy
Dissanayake, A. M., Wheldon, M. C., Ahmed, J., & Hood, C. J. (2017) · Kidney International Reports · doi:10.1016/j.ekir.2017.03.005 · Cited by 28
Effectiveness of shared goal setting and decision making to achieve treatment targets in type 2 diabetes patients: A cluster‐randomized trial ( OPTIMAL )
den Ouden, H., Vos, R. C., & Rutten, G. E. H. M. (2017) · Health Expectations · doi:10.1111/hex.12563 · Cited by 28
Study design and baseline characteristics of inpatients with diabetes mellitus in a tertiary hospital in China: A database study based on electronic medical records
Li, S., Yu, C., Li, Y., Li, Q., Zhang, R., Hou, Q., Zheng, T., Ma, Y., Wang, M., Su, N., et al. (2018) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12291 · Cited by 28
Effectiveness and safety of empagliflozin‐based quadruple therapy compared with insulin glargine‐based therapy in patients with inadequately controlled type 2 diabetes: An observational study in clinical practice
Ku, E. J., Lee, D., Jeon, H. J., & Oh, T. K. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13476 · Cited by 28
Conceptualizing multiple drug use in patients with comorbidity and multimorbidity: proposal for standard definitions beyond the term polypharmacy
Kadam, U. T., Roberts, I., White, S. J., Bednall, R., Khunti, K., Nilsson, P. M., & Lawson, C. A. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2018.10.014 · Cited by 28
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: P ost‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
Prato, S. D., Rosenstock, J., García‐Sánchez, R., Iqbal, N., Hansen, L., JOHNSSON, E. K., Chen, H., & Mathieu, C. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13258 · Cited by 28
Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (7th edition)
Dedov, I. I., Shestakova, M. V., Galstyan, G. R., Grigoryan, O. R., Esayan, R. M., Kalashnikov, V. Y., Кураева, Т. Л., Липатов, Д. В., Mayorov, A. Y., Peterkova, V. A., et al. (2015) · Diabetes Mellitus · doi:10.14341/dm7078 · Cited by 28
Pharmacologic Treatment of Type 2 Diabetes
Tran, L., Zielinski, A., Roach, A. H., Jende, J. A., Householder, A. M., Cole, E. E., Atway, S. A., Amornyard, M., Accursi, M. L., Shieh, S. W., et al. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015573010 · Cited by 27

Authors: Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R.
Affiliations: Yale New Haven Hospital (US)
Park Nicollet Health Services (US)
University of North Carolina at Chapel Hill (US)
Diabetes Center/Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands
University of Pisa (IT)
Diabeteszentrum Bad Lauterberg (DE)
University of Southern California (US)
Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece
American Cancer Society (US)
Churchill Hospital (GB)
Corresponding author: Inzucchi, Silvio E.
ORCID: Inzucchi, Silvio E.
Bergenstal, Richard M.
Buse, John B.
Ferrannini, Ele
Nauck, Michael
Peters, Anne L.
Wender, Richard
Matthews, David R.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2014-12-13
Volume: 38
Issue: 1
Pages: 140-149
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dc14-2441
OpenAlex: W2160088494
Cited by: 3,066
References: 68
Citations by year: 2026: 52 · 2025: 84 · 2024: 96 · 2023: 135 · 2022: 138 · 2021: 142 · 2020: 202 · 2019: 313 · 2018: 482 · 2017: 545 · 2016: 540 · 2015: 325 · 2014: 7
FWCI: 380.40
Type: journal article
Language: en
Open access: green
pure.amsterdamumc.nl
Licence: other-oa
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion, other-oa)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: Bristol-Myers Squibb
Eli Lilly and Company
AstraZeneca
GlaxoSmithKline
Sanofi
Massachusetts General Hospital
Yale University
Kaiser Permanente
F. Hoffmann-La Roche
Case Western Reserve University
School of Medicine, Case Western Reserve University
Intarcia Therapeutics
National Institute for Health and Care Research
University of Sydney
Universiteit van Amsterdam
University of Toronto
Novo Nordisk
Uniwersytet Łódzki
European Association for the Study of Diabetes
Université de Nantes
Servier
Lilly Deutschland
University of Ioannina
School of Medicine, University of Kansas
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: type 2 diabetes, hyperglycemia management, antidiabetic drugs, patient-centered care, shared decision-making, glucose-lowering agents, cardiovascular risk reduction, smoking cessation, blood pressure control, lipid control, statins, antiplatelet therapy, lifestyle modification
MeSH terms: Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Combinations, Humans, Hyperglycemia, Metformin, United States, Disease Management, Glycemic Index, Thiazolidinediones, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks